top of page

Pluristem contracts CRO for Phase I trial of PLX-R18

Pluristem has advanced its Phase I trial of PLX-R18 cells to treat insufficient haematopoietic recovery following haematopoietic cell transplantation (HCT) by contracting with a leading global clinical research organisation (CRO).

Click on this link for more information.



Today's News
Follow us
  • LinkedIn Social Icon
  • Vimeo Social Icon
Newsletter on Pharma Legislation
the newsletter of
bottom of page